An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naive to phosphodiesterase 5 inhibitor therapy

被引:15
作者
Bai, Wen-Jun [1 ]
Li, Hong-Jun [2 ]
Dai, Yu-Tian [3 ]
He, Xue-You [4 ]
Huang, Yi-Ran [5 ]
Liu, Ji-Hong [6 ]
Sorsaburu, Sebastian [7 ]
Ji, Chen [8 ]
Jin, Jian-Jun [8 ]
Wang, Xiao-Feng [1 ]
机构
[1] Peking Univ, Peoples Hosp, Dept Urol, Beijing 100871, Peoples R China
[2] Beijing Union Med Coll Hosp, Dept Urol, Beijing, Peoples R China
[3] Nanjing Drum Tower Hosp, Dept Androl, Nanjing, Jiangsu, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Dept Urol, Beijing 100853, Peoples R China
[5] Shanghai Renji Hosp, Dept Urol, Shanghai, Peoples R China
[6] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Urol, Wuhan 430074, Peoples R China
[7] Eli Lilly & Co, Dept Med, Indianapolis, IN 46285 USA
[8] Lilly Suzhou Pharmaceut Co Ltd, Dept Med, Shanghai, Peoples R China
关键词
erectile dysfunction; patient preference; phosphodiesterase; 5; inhibitors; PATIENT-PREFERENCE; EXTENDED DURATION; DOUBLE-BLIND; VARDENAFIL; EFFICACY; INTERCOURSE; PARTNERS; TRIAL;
D O I
10.4103/1008-682X.143244
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100221 [泌尿外科学];
摘要
The study was to compare treatment preference, efficacy, and tolerability of sildenafil citrate (sildenafil) and tadalafil for treating erectile dysfunction (ED) in Chinese men nave to phosphodiesterase 5 (PDE5) inhibitor therapies. This multicenter, randomized, open-label, crossover study evaluated whether Chinese men with ED preferred 20-mg tadalafil or 100-mg sildenafil. After a 4 weeks baseline assessment, 383 eligible patients were randomized to sequential 20-mg tadalafil per 100-mg sildenafil or vice versa for 8 weeks respectively and then chose which treatment they preferred to take during the 8 weeks extension. Primary efficacy was measured by Question 1 of the PDE5 Inhibitor Treatment Preference Questionnaire (PITPQ). Secondary efficacy was analyzed by PITPQ Question 2, the International Index of Erectile Function (IIEF) erectile function (EF) domain, sexual encounter profile (SEP) Questions 2 and 3, and the Drug Attributes Questionnaire. Three hundred and fifty men (91%) completed the randomized treatment phase. Two hundred and forty-two per 350 (69.1%) patients preferred 20-mg tadalafil, and 108/350 (30.9%) preferred 100-mg sildenafil (P < 0.001) as their treatment in the 8 weeks extension. Ninety-two per 242 (38%) patients strongly preferred tadalafil and 37/108 (34.3%) strongly the preferred sildenafil. The SEP2 (penetration), SEP3 (successful intercourse), and IIEF-EF domain scores were improved in both tadalafil and sildenafil treatment groups. For patients who preferred tadalafil, getting an erection long after taking the medication was the most reported reason for tadalafil preference. The only treatment-emergent adverse event reported by > 2% of men was headache. After tadalafil and sildenafil treatments, more Chinese men with ED nave to PDE5 inhibitor preferred tadalafil. Both sildenafil and tadalafil treatments were effective and safe.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 24 条
[1]
[Anonymous], CHIN J ANDROL
[2]
Bai Q, 2004, ASIAN J ANDROL, V6, P343
[3]
The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners [J].
Brock, Gerald ;
Chan, John ;
Carrier, Serge ;
Chan, Melanie ;
Salgado, Luis ;
Klein, Alexander H. ;
Lang, Clement ;
Horner, Richard ;
Gutkin, Stephen ;
Dickson, Ruth .
BJU INTERNATIONAL, 2007, 99 (02) :376-382
[4]
Phosphodiesterase type 5 inhibitors for erectile dysfunction [J].
Carson, CC ;
Lue, TF .
BJU INTERNATIONAL, 2005, 96 (03) :257-280
[5]
Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: The partners' preference study [J].
Conaglen, Helen M. ;
Conaglen, John V. .
JOURNAL OF SEXUAL MEDICINE, 2008, 5 (05) :1198-1207
[6]
Assessment of the relational factor in male patients consulting for sexual dysfunction: The concept of couple sexual dysfunction [J].
Corona, Giovanni ;
Petrone, Luisa ;
Mannucci, Edoardo ;
Magini, Angela ;
Lotti, Francesco ;
Ricca, Valdo ;
Chiarini, Valerio ;
Forti, Gianni ;
Maggi, Mario .
JOURNAL OF ANDROLOGY, 2006, 27 (06) :795-801
[7]
Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction: The Proper Drug for the Proper Patient [J].
Corona, Giovanni ;
Mondaini, Nicola ;
Ungar, Andrea ;
Razzoli, Elisa ;
Rossi, Andrea ;
Fusco, Ferdinando .
JOURNAL OF SEXUAL MEDICINE, 2011, 8 (12) :3418-3432
[8]
An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy [J].
Eardley, I ;
Mirone, V ;
Montorsi, F ;
Ralph, D ;
Kell, P ;
Warner, MR ;
Zhao, YL ;
Beardsworth, A .
BJU INTERNATIONAL, 2005, 96 (09) :1323-1332
[9]
Pharmacotherapy for Erectile Dysfunction [J].
Eardley, Ian ;
Donatucci, Craig ;
Corbin, Jackie ;
El-Meliegy, Amr ;
Hatzimouratidis, Konstantinos ;
McVary, Kevin ;
Munarriz, Ricardo ;
Lee, Sung Won .
JOURNAL OF SEXUAL MEDICINE, 2010, 7 (01) :524-540
[10]
IMPOTENCE AND ITS MEDICAL AND PSYCHOSOCIAL CORRELATES - RESULTS OF THE MASSACHUSETTS MALE AGING STUDY [J].
FELDMAN, HA ;
GOLDSTEIN, I ;
HATZICHRISTOU, DG ;
KRANE, RJ ;
MCKINLAY, JB .
JOURNAL OF UROLOGY, 1994, 151 (01) :54-61